U 100766

Each antimicrobial agent developed for clinical use during the past 60 years has ultimately encountered problems with the… Expand

Gram-positive (GP) cocci, mainly methicillin-resistant staphylococci, are the most frequent pathogens involved in central nervous… Expand

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This… Expand

ABSTRACT This randomized, double-blind, multicenter trial compared the efficacy and safety of linezolid, an oxazolidinone, with… Expand

The in-vitro activity of linezolid, a novel oxazolidinone, was investigated in comparison with those of amoxycillin, cefuroxime… Expand

ABSTRACT The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were… Expand

Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2… Expand

Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein… Expand

The new oxazolidinone antimicrobial agents U100592 and U100766 demonstrated good in vitro inhibitory activity against clinical… Expand

The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity… Expand